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Molecular Medicine SelectSmall noncoding RNAs, including endogenous antisense RNAs and microRNAs, are involved in many different cellular
processes. This issue’s Molecular Medicine Select highlights recent work investigating the roles of these RNAs in various
aspects of tumorigenesis, suggesting new prognostic, and possibly therapeutic, tools for treating cancer.
Myc Does It Again
MicroRNAs (miRNAs) are small noncoding RNAs that negatively regulate gene expression. While oncogenic and tumor
suppressor roles have been ascribed to some individual miRNAs, global changes in miRNA expression is commonly found
in tumor cells. How do miRNAs become dysregulated in tumors? Myc is a well-known oncogene that is activated in many
human tumors. Myc can either activate or repress gene expression by directly binding to DNA or inhibiting positive transcrip-
tion activators, respectively. Myc is known to activate transcription of a cluster of miRNAs that is amplified in lymphoma and
solid tumors. Using microarray analysis, Chang et al. (2008) now report a larger set of Myc-regulated miRNAs, the majority of
which are downregulated in Myc-inducible human and mouse B cell lymphoma lines. In addition to the previously reported
upregulated miRNAs, the authors note increased expression of one other miRNA, miR-7, and decreased expression of 13
miRNAs in the Myc-inducible lymphoma lines. Of the latter, 7 miRNAs are located in chromosomal regions known to be
deleted in cancer. A combination of chromatin immunoprecipitation (ChIP) and real-time PCR showed that Myc does bind
to at least one transcription start site for each of the 13Myc-repressedmiRNAs. But is decreased expression of thesemiRNAs
important in Myc-mediated tumorigenesis in vivo? Myc- and v-Abl-transformed B cells expressing five of the Myc-repressed
miRNAs, when injected into immunodeficient mice, did not contribute to tumor expansion. Meanwhile, miR-26a only de-
creased tumorigenesis in Myc-transformed cells, and miR-22 only affected tumorigenesis in v-Abl-transformed cells. The
mechanism by which these miRNAs inhibit tumorigenesis remains to be elucidated. Together these data implicate the Myc
oncogene in the repression of miRNAs that possess antitumorigenic properties. They also support the notion that the wide-
spread downregulation of miRNAs seen in cancer promotes tumorigenesis and is not merely a side effect of transformation.
T.-C. Chang et al. (2008). Nature Genet. 40, 43–50.
miRNAs Promote Metastasis
It turnsout thatmiRNAsmay regulatenotonlycancercell invasiveness (directmigrationandpen-
etration by cancer cells into neighboring tissues) but also tumor metastasis (the process of can-
cer cells leaving the site of origin andmigrating to other locations). Huanget al. (2008) performed
a genetic screen to identify miRNAs that induce a nonmetastatic human breast tumor cell line
(MCF-7) to invade andmigrate in culture assays. Of approximately 450miRNA-expressing vec-
tors that were tested by transduction into MCF-7 cells, expression of miR-373, miR-520c, and
miR-520e induced migration and promoted invasiveness. The miR-373 miRNA has been previ-
ously implicated as anoncogene in testicular germ-cell tumors. Threemigratory cancer cell lines
(breast, prostate, and colon) expressed endogenous miR-373 (but not miR-520); reduced ex-
pression of miR-373 (via an antisense oligonucleotide against miR-373) resulted in decreased
cellmigration. Expression ofmiR-373 andmiR-520c inMCF-7 cells, which are not normallymet-
astatic, induced tumors in remote locations when injected into immunodeficient mice. What are
the targets of these miRNAs? Multiple lines of evidence suggest that miR-373 and miR-520c
downregulate the expression of CD44, a cell-surface receptor for the glycoprotein hyaluronan.
Although CD44 is unlikely to be the only target of these two miRNAs, it is clear that decreased
expression of CD44 does contribute to increased tumor cell migration and invasion. Increased
expression of CD44 is known to correlate with breast cancer patient survival and to suppress
metastasis of prostate and colon cancer cells. Huang et al. demonstrate that increased expres-
sion of miR-373 correlates with metastasis of breast tumor cells to lymph node tissue, whereas
CD44 expression in the breast tumor cells decreases metastasis to lymph nodes. Together the
data suggest thatmiR-373 andmiR-520may regulate the expression of CD44, a surface protein whose expression is known to
decrease metastatic potential. The fact that an anti-miR oligonucleotide reduces tumor cell migration in vitro may open new
avenues for cancer treatment.
Q. Huang et al. (2008). Nat. Cell Biol. 10, 202–210.
.And They Suppress Metastasis, Too
Genes that mediate metastasis have been identified and characterized, but less is known about how these genes are down-
regulated in tumor cells. Tavazoie et al. (2008) now report that expression of six miRNAs is decreased in breast cancer cell
lines that are highly metastatic to bone or lung. Importantly, expression of any of these three miRNAs (miR-335, miR-126,
or miR-206) decreased the metastatic activity of both tumor cell lines. Metastasis requires cell proliferation, survival, and
migration, so the authors investigated at which of these steps the threemiRNAsmight be operating. Only miR-126 expression
suppressed tumor growth, which was attributed to a decrease in proliferation but not apoptosis. Meanwhile, expression of
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miR-335 and miR-206 reduced tumor cell migration and invasiveness. This suggests
that these miRNAs play different roles in blocking metastasis. In tissue samples from
breast cancer patients, expression of all three miRNAs is decreased, with the lowest
expression correlating with shorter relapse-free intervals and poor survival. What
genes do these miRNAs regulate? Expression profiling identified six candidate genes
for miR-335 (targets of the other miRNAs were not reported). These genes encode
type 1 collagen COLIA1, receptor-type tyrosine protein phosphatase PTPRN2, the
c-Mer tyrosine kinase, the phospholipase PLCB1, tenascin C, and the transcription
factor SOX4. Reporter and cell-based assays confirmed that SOX4, PTPRN2,
c-Mer tyrosine kinase and potentially tenascin C are direct targets ofmiR-335. Reduc-
ing the expression of SOX4 or tenascin C in metastatic breast cancer cells decreased
migration, invasive ability, and metastasis. These data suggest that miR-335 regu-
lates metastasis by suppressing metastatic genes, including SOX4 and tenascin C.
It will be interesting to learn the targets of the other miRNAs identified in this study,
and to see whether this information can be translated into more accurate prognostic
assays.
S. Tavazoie et al. (2008). Nature 451, 147–152.
Prognostic miRNA Signatures
Altered expression of miRNAs has been found in many different types of tumors, and
miRNA signatures have been reported for chronic lymphocytic leukemia, lung adeno-
carcinoma, and breast and pancreatic cancer. Now, Yu et al. (2008) demonstrate that
a signature of five miRNAs can predict the clinical outcome of non-small-cell lung
carcinoma (NSCLC). Using regression analysis, the authors determine that five
miRNAs are associated with the survival of NSCLC patients. These include two protective miRNAs (hsa-miR-221 and hsa-
let-7a) and three ‘‘high-risk’’miRNAs (hsa-miR-137, hsa-miR-372, andhsa-mir-182*). The authors then validated this signature
with independent patient samples. Patients with high-riskmiRNA signatures had shorter survival times than patients with low-
risk signatures. To demonstrate that these fivemiRNAs doplay a role in cancer, Yu et al. looked at their possible involvement in
cancer cell invasiveness (a function notpreviously associatedwithmiRNAs). Transfectionof eachof the threehigh-riskmiRNAs
increased the invasive ability of a lung cancer cell line that does not normally show this characteristic. In contrast, expression of
the protective miRNA, hsa-miR-221, decreased the invasiveness of a high-invasive cell line. However, the protective miRNA
hsa-let-7a did not boost the invasiveness of the metastatic lung cancer cell line, perhaps indicating that it may be involved
in other aspects of cancer growth or progression. These data have important implications for screening cancer patients,
identifying those at high risk and selecting the best chemotherapy regimen.
S.-L. Yu et al. (2008). Cancer Cell 13, 48–57.
Antisense RNA Makes Sense of Silencing
Tumor-suppressor genes are frequently silenced epigenetically in tumor cells. Although DNA methylation is often associated
with silencing of tumor-suppressor genes, to date mutations in the DNA methylation machinery of tumors have not been re-
ported. Because noncoding RNAs (including mRNAs and antisense RNAs) present a potential mechanism for gene silencing,
Yu et al. (2008) asked if endogenous antisense RNAs (endogenous transcripts with sequences complementary to sense tran-
scripts) lead to silencingof tumor-suppressorgenes in tumors. First, they identifiedantisenseRNA transcripts for 21well-known
tumor-suppressor genes. Focusing on one, p15, the authors confirmed the expression of endogenous p15 antisense (p15AS)
RNA in two leukemia cell lines and in leukemia patient tissue samples, which displayed increased p15AS expression and de-
creased p15 expression. Transfection of p15AS downregulates transfected p15 in colon carcinoma cells. The p15ASRNA ap-
pears toplaya role in the initiation, butnot themaintenance,ofp15silencing. Interestingly, nochanges inDNAmethylationof the
p15 promoter were found in p15-transfected cell lines, but alterations in histone methylation were found at the p15 promoter.
This suggests that antisense RNAmay induce heterochromatin formation at promoters, leading to gene silencing. Introduction
of p15AS into embryonic stem cells produces results similar to those seen with cell lines (decreased p15 expression and alter-
ations in histonemethylation). However, once the stem cells differentiate into embryoid bodies, the p15 promoter becomes hy-
permethylated, a result not seen in cell lines, indicating that DNAmethylationmay be a secondary effect to histonemethylation.
When the transfected embryonic stem cells were cultured individually, they exhibited increased growth rates. Together, these
data suggest that even transient ‘‘doses’’ of antisense RNA can induce long-lasting gene silencing of tumor suppressor genes.
AntisenseRNAsmayhavepotential asdiagnosticmarkers forcancer risk andmaybeuseful targets fordeveloping therapeutics.
W. Yu et al. (2008). Nature 451, 202–206.
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